Literature DB >> 15963075

Review article: the changing epidemiology of hepatocellular carcinoma in Canada.

Z Dyer1, K Peltekian, S Veldhuyzen van Zanten.   

Abstract

The aim of this study was to examine the incidence of and mortality caused by hepatocellular carcinoma over the last 20 years in Canada, including the associated risk factors hepatitis C, diabetes and obesity. Databases from the Surveillance & Risk Assessment Division of Health Canada & Statistics Canada were analysed for trends in both age-adjusted incidence of and mortality due to hepatocellular carcinoma from 1984 to 2001. The epidemiological impact of hepatitis C, diabetes and obesity on hepatocellular carcinoma was also assessed. The incidence of hepatocellular carcinoma increased from 4.0 per 100,000 in 1984 to 5.5 in 2,000 for males, and from 1.6 per 100,000 in 1984 to 2.2 in 2,000 for females. Mortality rates showed a 48% increase in males and 39% increase in females. The incidence of hepatitis C increased sharply in 1995 and remained elevated until 2,000 with an average value of 85.4 per 100,000 in males and 45.4 per 100,000 in females. This increase is likely due to the widespread testing for hepatitis C. The prevalence of obesity and diabetes has increased in recent years and probably contributes to the increased incidence of hepatocellular carcinoma. The incidence of hepatocellular carcinoma in Canada has increased in the past 20 years and is associated with a rise in the incidence of hepatitis C, obesity and diabetes.

Entities:  

Mesh:

Year:  2005        PMID: 15963075     DOI: 10.1111/j.1365-2036.2005.02504.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  16 in total

1.  Trends in relative survival in patients with a diagnosis of hepatocellular carcinoma in Ontario: a population-based retrospective cohort study.

Authors:  Hla-Hla Thein; Edwin Khoo; Michael A Campitelli; Ahmad Zaheen; Qilong Yi; Prithwish De; C C Earle
Journal:  CMAJ Open       Date:  2015-04-02

2.  Type 2 diabetes, smoking, insulin use, and mortality from hepatocellular carcinoma: a 12-year follow-up of a national cohort in Taiwan.

Authors:  Chin-Hsiao Tseng
Journal:  Hepatol Int       Date:  2012-10-06       Impact factor: 6.047

Review 3.  Advances in managing hepatocellular carcinoma.

Authors:  Marielle Reataza; David K Imagawa
Journal:  Front Med       Date:  2014-05-08       Impact factor: 4.592

4.  Long-term effect of stereotactic body radiation therapy for primary hepatocellular carcinoma ineligible for local ablation therapy or surgical resection. Stereotactic radiotherapy for liver cancer.

Authors:  Jung Hyun Kwon; Si Hyun Bae; Ji Yoon Kim; Byung Ock Choi; Hong Seok Jang; Jeong Won Jang; Jong Young Choi; Seung Kew Yoon; Kyu Won Chung
Journal:  BMC Cancer       Date:  2010-09-03       Impact factor: 4.430

5.  Canadian trends in liver cancer: a brief clinical and epidemiologic overview.

Authors:  P De; D Dryer; M C Otterstatter; R Semenciw
Journal:  Curr Oncol       Date:  2013-02       Impact factor: 3.677

6.  Exponential enhancement of oncolytic vesicular stomatitis virus potency by vector-mediated suppression of inflammatory responses in vivo.

Authors:  Jennifer Altomonte; Lan Wu; Li Chen; Marcia Meseck; Oliver Ebert; Adolfo García-Sastre; John Fallon; Savio L C Woo
Journal:  Mol Ther       Date:  2007-12-11       Impact factor: 11.454

7.  Enhanced oncolytic potency of vesicular stomatitis virus through vector-mediated inhibition of NK and NKT cells.

Authors:  J Altomonte; L Wu; M Meseck; L Chen; O Ebert; A Garcia-Sastre; J Fallon; J Mandeli; S L C Woo
Journal:  Cancer Gene Ther       Date:  2008-10-10       Impact factor: 5.987

8.  Trends in health care utilization and costs attributable to hepatocellular carcinoma, 2002-2009: a population-based cohort study.

Authors:  H H Thein; Y Qiao; S K Young; W Zarin; E M Yoshida; C de Oliveira; C C Earle
Journal:  Curr Oncol       Date:  2016-06-09       Impact factor: 3.677

9.  Engineered newcastle disease virus as an improved oncolytic agent against hepatocellular carcinoma.

Authors:  Jennifer Altomonte; Sabrina Marozin; Roland M Schmid; Oliver Ebert
Journal:  Mol Ther       Date:  2009-10-06       Impact factor: 11.454

Review 10.  Radiofrequency ablation versus hepatic resection for the treatment of early-stage hepatocellular carcinoma meeting Milan criteria: a systematic review and meta-analysis.

Authors:  Chenyang Duan; Mengying Liu; Zhuohang Zhang; Kuansheng Ma; Ping Bie
Journal:  World J Surg Oncol       Date:  2013-08-13       Impact factor: 2.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.